Table 2 Study objectives
Primary objective | To assess the treatment effect of L-BLP25 plus BSC, as compared to BSC alone, on overall survival time |
Secondary objectives | Time to symptom progression (based on LCSS questionnaire) |
| Â | Time to progression |
| Â | Progression-free survival time |
| Â | Time to treatment failure |
| Â | Safety |
Other objectives | Quality-of-life (EQ-5D/LCSS) |
| Â | Healthcare resource utilization and work status |
| Â | Biomarkers/pharmacogenetics |